

Neuland Laboratories Limited 11th Floor, (5th Office Level), Phoenix IVY Building, Plot No. 573A-III, Road No.82, Jubilee Hills, Hyderabad-500033, Telangana, India

Tel: 040 67611600 / 67611700 Email: neuland@neulandlabs.com www.neulandlabs.com

June 1, 2022

The National Stock Exchange of India Ltd Exchange Plaza, Bandra Kurla Complex Bandra (E), Mumbai - 400 001

Scrip Code: NEULANDLAB; Series: EQ

Dear Sir/Mam,

Submission of half yearly disclosure on Related Party Transactions pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations)

We refer to our submission of Related Party Transactions pursuant to Regulation 23(9) of SEBI Listing Regulations, 2015 through XBRL on May 20, 2022. Further, as required by you vide your email dated May 27, 2022, please find enclosed herewith the disclosure on Related Party Transactions for the half year ended March 31, 2022.

Request you to treat the above as complied.

HYDERABAD

This is for your information and records.

Thanking you,

Yours sincerely,

For Neuland Laboratories Limited

Sarada Bhamidipati

Company Secretary

Encl: As above

CC: BSE Limited, Phiroze Jeejeebhoy Towers, 25th Floor, Dalal Street, Mumbai - 400 001 Scrip Code: 524558

(Rs. lakhs)

											Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.							
S.No.	Details of the party (listed entity /subsidiary) entering Details of the counterparty					V-1	In case monies are due to either					Details of the loans, inter-corporate deposits, advances or investments						
-	Name	PAN	Name	PAN	Relationship of the counterparty	Type of related party transaction (see Note 5)	Value of the related party transaction as approved by the audit committee (see Note 6a)		party as a result of the transaction  g Opening balance Closing balance		loans, inter-corporate deposits, advances or investments  Nature of indebtedness Cost Tenure		Nature	Interest Rate	Tenure	Secured/	Purpose for which the funds will	
					with the listed entity or its subsidiary				Opening balance closing balance	(loan/ issuance of debt/ any other etc.)	(see Note 7)	renare	(loan/ advance/ inter-corporate deposit/ investment		Tenare	unsecured	be utilised by the ultimate recipient of funds (end-usage)	
1	Neuland Laboratories Limited	AAACN9531E	Dr. Davuluri Rama Mohan Rao	ABVPD5600P	Executive Chairman and KMP	Remuneration	As per the Companies Act, 2013 and Shareholders' Approval	230.00	-	-130.0	0							
2	Neuland Laboratories Limited	AAACN9531E	Mr. Davuluri Sucheth Rao	ABAPD1690G	Vice-Chairman & CEO and KMP	Remuneration	As per the Companies Act, 2013 and Shareholders' Approval	212.50	-1.89	-125.0	0							
3	Neuland Laboratories Limited		Mr. Davuluri Saharsh Rao	AHVPD9296R	Vice-Chairman & Managing Director and KMP	Remuneration	As per the Companies Act, 2013 and Shareholders' Approval	212.50		-125.0								
4	Neuland Laboratories Limited	AAACN9531E	Mr. Parampally Vasudeva Maiya	AAPPM8429F	Non-Executive Independent Director	Commission	11.4		-	-5.0								
5	Neuland Laboratories Limited	AAACN9531E	Mr. Humayun Dhanrajgir	AAAPD8407E	Non-Executive Independent Director	Sitting fees and Commission	13.10		-	-5.0								
6	Neuland Laboratories Limited	AAACN9531E	Mrs. Bharati Rao	ABEPR3693M	Non-Executive Independent Director	Sitting fees and Commission	13.10		-	-5.0								
7	Neuland Laboratories Limited	AAACN9531E	Dr. Nirmala Murthy	AHSPM5003A	Non-Executive Independent Director	Sitting fees and Commission	13.10	8.10	-	-5.0	0							
8	Neuland Laboratories Limited	AAACN9531E	Dr. William Gordon Mitchell	FEZPM2196K	Non-Executive Independent Director	Sitting fees and Commission	10.5		1	-5.0								
9	Neuland Laboratories Limited	AAACN9531E	Dr. Christopher M Cimarusti	CAZPC2683Q	Non-Executive Non-Independent Director	Sitting fees and Commission	11.50		-	-5.0								
10	Neuland Laboratories Limited	AAACN9531E	Mr. Homi Rustam Khusrokhan	AFQPK7415N	Non-Executive Independent Director	Commission	13.10		-	-5.0	0							
11	Neuland Laboratories Limited		Mr. Deepak Gupta	AFYPG0503K	Chief Financial Officer and KMP	Remuneration	Not Applicable				-							
12	Neuland Laboratories Limited		Mrs. Davuluri Vijaya Rao	ABPPD8725M	Relative of Director Vice-Chairman & CEO and KMP	Office Lease rent	47.29			-7.2	1	l	1			1		
14	Neuland Laboratories Limited Neuland Laboratories Limited	AAACN9531E AAACN9531E	Mr. Davuluri Sucheth Rao Mr. Davuluri Saharsh Rao	ABAPD1690G AHVPD9296R	Vice-Chairman & CEO and KMP  Vice-Chairman & Managing Director and KMP	Office Lease rent Office Lease rent	63.8				-							
15		AAACN9531E			Vice-Chairman & CEO and KMP	Security Deposit given			121.40									
	Neuland Laboratories Limited		Mr. Davuluri Sucheth Rao	ABAPD1690G			121.4	p		121.4	0							
16	Neuland Laboratories Limited	AAACN9531E	Mr. Davuluri Saharsh Rao	AHVPD9296R	Vice-Chairman & Managing Director and KMP	Security Deposit given	121.4		121.40	121.4	0							
17	Neuland Laboratories Limited	AAACN9531E	Mrs. Davuluri Vijaya Rao	ABPPD8725M	Relative of Promoters	Security Deposit given	19.20		19.20	19.20								
18	Neuland Laboratories Limited	AAACN9531E	Neuland Laboratories INC		Wholly owned subsidiary	Business Promotion	Not Applicable			-449.2								
19 19	Neuland Laboratories Limited Neuland Laboratories Limited	AAACN9531E AAACN9531E	Neuland Laboratories KK Neuland Laboratories KK		Wholly owned subsidiary Wholly owned subsidiary	Business Promotion Advance	Not Applicable Not Applicable		-133.23 14.79	-77.20 14.79								